Derek Hicks Receives Stock Award at Intellia Therapeutics Inc (NTLA) — SEC Form 4, Mar 03, 2023

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Derek Hicks

EVP

TXN 2023-03-01 · FILED 2023-03-03

Equity Position 40.9K sh 17,306 → 40,864

Equity Change +136.1% shares held after vs before

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Intellia Therapeutics Inc

NTLA CIK 0001652130

Reporting Owner

Name	Relationship
Derek Hicks CIK 0001901282	EVP

Derek Hicks at Intellia Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at Intellia Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1	2023-03-01	A - Award/Grant	23,558 A	$0.00	—	40,864	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock option (right to buy)F2	$40.75	2023-03-01	A - Award/Grant	33,287 A	$0.00	2033-02-28	33,287 Common Stock	Direct

Footnotes (2)

F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Show more
F2: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 5 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Intellia Therapeutics Inc

GET /v1/forms/4/0001209191-23-015817 API docs